In a meta-analysis, it was demonstrated that 40.9% of SVT and 41.1% of BCS have an underlying MPN and 41.1% of PVT and 27.7% of BCS patients have the JAK2 V617F mutation [7]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.